Short Interest in Fresenius Medical Care AG (NYSE:FMS) Declines By 5.1%

Fresenius Medical Care AG (NYSE:FMS) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 808,800 shares, a decline of 5.1% from the November 30th total of 852,500 shares. Based on an average daily volume of 272,600 shares, the days-to-cover ratio is presently 3.0 days.

Analysts Set New Price Targets

Several research analysts have weighed in on FMS shares. StockNews.com began coverage on Fresenius Medical Care in a research note on Thursday, November 28th. They issued a “strong-buy” rating for the company. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target for the company. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Truist Financial boosted their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.30.

Fresenius Medical Care Stock Down 1.1 %

Shares of NYSE:FMS opened at $22.71 on Tuesday. The stock has a 50-day simple moving average of $22.13 and a 200-day simple moving average of $20.60. The stock has a market capitalization of $13.33 billion, a P/E ratio of 18.77, a PEG ratio of 0.96 and a beta of 0.94. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors have recently made changes to their positions in FMS. Creative Planning raised its stake in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after buying an additional 6,373 shares during the period. Verition Fund Management LLC bought a new stake in shares of Fresenius Medical Care in the third quarter valued at approximately $237,000. Wulff Hansen & CO. lifted its position in shares of Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Fresenius Medical Care by 11.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after purchasing an additional 2,233 shares during the period. Finally, Quantinno Capital Management LP lifted its holdings in shares of Fresenius Medical Care by 78.9% during the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after acquiring an additional 48,554 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.